3 results
Approved WMOCompleted
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
Approved WMOPending
Primary Objective: • To contrast Coherent Mapping quality (electrograms per map) and noise assessment using Octaray (with TRUEREF technology) versus Pentaray catheter for left and right atrium.Secondary Objective(s): • To contrast the Coherent…
Approved WMOPending
To prospectively investigate if a treatment strategy in which two types of cytotoxic RLT, i.e., an alpha-emitter and a beta-emitter, are alternatively offered to patients with oligometastatic HSPCa, is feasible and safe